Loading organizations...
Key people at Vaximm AG.
Vaximm AG was founded in 2008 by Klaus Breiner (Co-Founder & Vice-Chairman (Executive Chairman till mid-2016)).
Vaximm AG is a biotechnology firm focused on developing oral T-cell immunotherapies for the treatment of various cancers. The company's innovative platform leverages the gut immune system to generate systemic precision cytotoxic immune responses, combining the convenience of oral administration with potent anti-tumor effects designed to target solid tumors effectively.
The company was co-founded by Klaus Breiner and Andreas Niethammer. Dr. Niethammer, a noted expert in oncology, established Vaximm with the strategic insight to translate his pioneering research conducted at The Scripps Research into therapeutic applications. This foundational idea centered on the potential of the gut immune system to serve as a powerful engine for novel cancer immunotherapies.
Vaximm's therapies are intended for cancer patients, aiming to provide accessible and transformative treatment alternatives. The company's long-term vision is to establish a new class of effective, orally administered immunotherapies that can significantly enhance patient outcomes and broaden the therapeutic landscape for challenging cancers, moving towards more functional and patient-friendly solutions.
Vaximm AG is a Swiss biotechnology company developing *oral T‑cell immunotherapies* (therapeutic vaccines) that use attenuated bacteria to deliver tumor antigens and activate cytotoxic T cells against cancer; its lead candidate VXM01 targets tumor vasculature (VEGFR2) and has progressed in early clinical testing while a broader pipeline explores neoantigen and shared‑antigen programs[5][2][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Oncology Landscape
Quick Take & Future Outlook
If you’d like, I can:
Vaximm AG was founded in 2008 by Klaus Breiner (Co-Founder & Vice-Chairman (Executive Chairman till mid-2016)).
Key people at Vaximm AG.